Intel reports upbeat revenue guidance; scales back chip factory construction plans
CareDx, Inc. (Nasdaq: NASDAQ:CDNA) today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action.
In a Court document unsealed on October 7, 2024, the DOJ indicated that it is declining to intervene in a qui tam action filed by a former CareDx employee.
Today's decision by the DOJ follows the decision made by the U.S. Securities and Exchange Commission (SEC) in September 2023 to close its investigation and take no action against the Company. The Company believes the closure of the DOJ’s investigation underscores that the underlying allegations, which have now been reviewed by two separate government agencies, were meritless, reinforcing its confidence in the integrity of its operations.
The qui tam complaint, which was filed under seal on February 12, 2021, in the federal district court for the Eastern District of New York, is now unsealed. CareDx will continue to vigorously defend itself should the former employee choose to proceed with this litigation.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.
CDNA: A Bull or Bear Market Play?
Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year..
In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record.
With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies.
So if CDNA is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.